Evidence map›Paper›PMID 35921474›Full record

ArticleScience translational medicine2022

Triple-negative breast cancer metastasis involves complex epithelial-mesenchymal transition dynamics and requires vimentin.

Eloïse M Grasset, Matthew Dunworth, Gaurav Sharma, Melanie Loth, Joseph Tandurella, Ashley Cimino-Mathews, Melissa Gentz, Sydney Bracht, Meagan Haynes, Elana J Fertig and 1 more

Open access · greenAbstract read
In one paragraph

Article in Science translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 132 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
132citing papers in PubMed, 2 pooled it
18.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

132 citing papers in PubMed, 2 syntheses or guidelines pooled it, 180 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Enhanced anticancer efficacy ofMaterials today. Bio · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

72 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Eloïse M GrassetDepartment of Cell Biology, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.ORCID 0000-0001-9857-582X
Matthew DunworthDepartment of Cell Biology, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.ORCID 0000-0002-8852-169X
Gaurav SharmaDepartment of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.ORCID 0000-0002-4326-5231
Melanie LothDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0003-2717-8258
Joseph TandurellaDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0002-5806-6681
Ashley Cimino-MathewsDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Melissa GentzDepartment of Cell Biology, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.ORCID 0000-0003-1800-4002
Sydney BrachtDepartment of Cell Biology, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.
Meagan HaynesDepartment of Cell Biology, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.
Elana J FertigDepartment of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.ORCID 0000-0003-3204-342X
Andrew J EwaldDepartment of Cell Biology, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.ORCID 0000-0002-1964-0740
Johns Hopkins University · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
Tech Core 2U54CA268083 · NCI · JOHNS HOPKINS UNIVERSITY · PI Andrew Josef Ewald · 2022 to 2026
$10.2M
Pathway Discovery and Target Validation for Outgrowth of Breast Cancer MetastasesU01CA217846 · NCI · JOHNS HOPKINS UNIVERSITY · PI BADER, JOEL S., EWALD, ANDREW JOSEF · 2017 to 2021
$4.8M
Integrating bioinformatics into multiscale models for hepatocellular carcinomaU01CA212007 · NCI · JOHNS HOPKINS UNIVERSITY · PI EWALD, ANDREW JOSEF, FERTIG, ELANA · 2018 to 2022
$3.2M
Single-cell and imaging data integration software to spatially resolve the tumor microenvironmentU01CA253403 · NCI · JOHNS HOPKINS UNIVERSITY · PI FERTIG, ELANA · 2020 to 2022
$1.2M
NCI NIH HHS P30 CA006973NCI NIH HHS U01 CA212007NCI NIH HHS U01 CA217846NCI NIH HHS U01 CA253403NCI NIH HHS U54 CA268083
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is an aggressive subtype associated with early metastatic recurrence and worse patient outcomes. TNBC tumors express molecular markers of the epithelial-mesenchymal transition (EMT), but its requirement during spontaneous TNBC metastasis in vivo remains incompletely understood. We demonstrated that spontaneous TNBC tumors from a genetically engineered mouse model (GEMM), multiple patient-derived xenografts, and archival patient samples exhibited large populations in vivo of hybrid E/M cells that lead invasion ex vivo while expressing both epithelial and mesenchymal characteristics. The mesenchymal marker vimentin promoted invasion and repressed metastatic outgrowth. We next tested the requirement for five EMT transcription factors and observed distinct patterns of utilization during invasion and colony formation. These differences suggested a sequential activation of multiple EMT molecular programs during the metastatic cascade. Consistent with this model, our longitudinal single-cell RNA analysis detected three different EMT-related molecular patterns. We observed cancer cells progressing from epithelial to hybrid E/M and strongly mesenchymal patterns during invasion and from epithelial to a hybrid E/M pattern during colony formation. We next investigated the relative epithelial versus mesenchymal state of cancer cells in both GEMM and patient metastases. In both contexts, we observed heterogeneity between and within metastases in the same individual. We observed a complex spectrum of epithelial, hybrid E/M, and mesenchymal cell states within metastases, suggesting that there are multiple successful molecular strategies for distant organ colonization. Together, our results demonstrate an important and complex role for EMT programs during TNBC metastasis.

Indexed as

Triple Negative Breast NeoplasmsAnimalsCell Line, TumorCell MovementCell ProliferationEpithelial-Mesenchymal TransitionHumansMiceNeoplasm MetastasisVimentinVimentin

Identifiers

PMID35921474
PMCPMC9801390
OpenAlexW4289637826

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.